Department of Orthopedics and Traumatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Sci Rep. 2019 Feb 14;9(1):2089. doi: 10.1038/s41598-018-38335-3.
Falls in late postmenopausal women with osteopenia usually cause fractures with severe consequences. This 36-month randomized, double-blind and placebo-controlled trial with a 10-year observational follow-up study aimed to investigate the long-term effect of herbal formula Bushen Yijing Fang (BSYJF) on fall risk in the late postmenopausal women with osteopenia. 140 late postmenopausal women (Femoral neck T-score, -2.5~-2 SD) were recruited and randomized to orally receive calcium carbonate 300 mg daily with either BSYJF or placebo for 36 months. The effect was further investigated for another 10-year follow-up. During the 36-month administration, there were 12 falls in BSYJF group and 28 falls in placebo group, respectively, indicating 64% lower risk of falls (RR 0.36 [95% CI, 0.18 to 0.71]; P = 0.004) in BSYJF group. During the 10-year follow-up, 36% lower fall risk (RR 0.64 [95% CI, 0.46 to 0.89]; P = 0.009) was observed in BSYJF group. No significant difference was found in safety profile between two groups. Thirty-six-month administration of BSYJF reduced fall risk with an increase in bone mass, and its latent effect on fall risk was continually observed in the 10-year follow-up in late postmenopausal women with osteopenia. This clinical trial was registered at Chinese clinical trial registry (ChiCTR-IOR-16008942).
在患有骨质疏松症的绝经后期妇女中,跌倒通常会导致严重后果的骨折。本项为期 36 个月的随机、双盲、安慰剂对照试验,以及 10 年的观察随访研究,旨在探讨补肾益精方(BSYJF)对患有骨质疏松症的绝经后期妇女跌倒风险的长期影响。共招募了 140 名绝经后期妇女(股骨颈 T 评分,-2.5~-2SD),并将其随机分为两组,分别口服碳酸钙 300mg 每日,同时分别接受 BSYJF 或安慰剂治疗 36 个月。进一步对另外 10 年的随访进行了研究。在 36 个月的治疗期间,BSYJF 组有 12 例跌倒,安慰剂组有 28 例跌倒,BSYJF 组的跌倒风险降低了 64%(RR 0.36 [95% CI, 0.18 至 0.71];P=0.004)。在 10 年的随访期间,BSYJF 组的跌倒风险降低了 36%(RR 0.64 [95% CI, 0.46 至 0.89];P=0.009)。两组之间的安全性特征无显著差异。BSYJF 的 36 个月治疗降低了跌倒风险,并增加了骨量,在患有骨质疏松症的绝经后期妇女中,其对跌倒风险的潜在影响在 10 年的随访中持续观察到。本临床试验在中国临床试验注册中心(ChiCTR-IOR-16008942)注册。